Open Access Repository
The host microbiome and impact of tuberculosis chemotherapy

Full text not available from this repository.
Abstract
The treatment of Mycobacterium tuberculosis infection is often viewed in isolation from other human microbialsymbionts. Understandably, the clinical priority is eliminating active or latent tuberculosis (TB) in patients. Withthe increasing resolution of molecular biology technologies, it is becoming apparent that antibiotic treatmentcan perturb the homeostasis of the host microbiome. For example, dysbiosis of the gut microbiota has beenassociated with an increased risk of the development of asthma, obesity and diabetes. Therefore, fundamentalquestions include: Does TB chemotherapy cause disruption of the human microbiome and adverse effects inpatients; and are there signature taxa of dysbiosis following TB treatment. In this review, we examine recentresearch on the detection of changes in the microbiome during antibiotic administration and discuss specificfindings that relate to the impact of anti-tubercular chemotherapy.
Item Type: | Article |
---|---|
Authors/Creators: | O'Toole, R and Gautam, SS |
Keywords: | Mycobacterium tuberculosis; microbiome; antibiotic |
Journal or Publication Title: | Tuberculosis |
Publisher: | Churchill Livingstone |
ISSN: | 1472-9792 |
DOI / ID Number: | 10.1016/j.tube.2018.08.015 |
Copyright Information: | © 2018 Elsevier Ltd |
Related URLs: | |
Item Statistics: | View statistics for this item |
Actions (login required)
![]() |
Item Control Page |